The frequency and impact of FGFR1 amplification on clinical outcomes in Korean patients with small cell lung cancer

Ji Soo Park, Jae Seok Lee, Eun Young Kim, Ji Ye Jung, Se Kyu Kim, Joon Chang, Dae Joon Kim, Chang Young Lee, Inkyung Jung, Joo Hang Kim, Hye Ryun Kim, Yong Wha Moon, Hyo Song Kim, Byoung Chul Cho, Hyo Sup Shim

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objectives: Fibroblast growth factor receptor 1 (FGFR1) plays a critical role in many human cancers. We tried to identify the frequency of FGFR1 amplifications among Korean patients with small cell lung cancer (SCLC). Additionally, we examined the clinical significance of FGFR1 amplifications for overall survival (OS) and progression-free survival (PFS) among SCLC patients who received standard chemotherapies. Materials and methods: Tumor tissues from 158 Korean patients diagnosed with SCLC from September 2009 to February 2013 were collected and analyzed using an FGFR1 FISH assay with a probe that hybridized to chromosome region 8p12-8p11.23 (Abbott Molecular, Abbott Park, IL). Results and conclusion: FGFR1 amplification was detected in three patients (1.9%) harboring extensive disease (ED). A multivariate analysis showed that among the patients with ED, FGFR1 amplification was associated with shorter disease-free survival to first-line chemotherapy with etoposide plus cisplatin or carboplatin (hazard ratio [HR] = 7.1; 95% confidence interval [CI] = 2.0-25.4; P = 0.003). The median overall survival time of the patients with ED was 8.2 and 10.2 months among patients with and without FGFR1 amplification, respectively (P = 0.37). Although FGFR1 amplification is rare in SCLC compared to non-small cell lung cancer or other malignancies with squamous histology, it is associated with poor survival following standard chemotherapy in SCLC. Further studies in large cohorts of patients with SCLC are needed to verify these results. Our results imply that FGFR1 may be a potential therapeutic target in SCLC and it could be confirmed in a clinical trial.

Original languageEnglish
Pages (from-to)325-331
Number of pages7
JournalLung Cancer
Volume88
Issue number3
DOIs
Publication statusPublished - 2015 Jun 1

Fingerprint

Receptor, Fibroblast Growth Factor, Type 1
Small Cell Lung Carcinoma
Drug Therapy
Disease-Free Survival
Survival
Neoplasms
Carboplatin
Etoposide
Non-Small Cell Lung Carcinoma
Cisplatin
Histology
Multivariate Analysis
Chromosomes
Clinical Trials
Confidence Intervals

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Park, J. S., Lee, J. S., Kim, E. Y., Jung, J. Y., Kim, S. K., Chang, J., ... Shim, H. S. (2015). The frequency and impact of FGFR1 amplification on clinical outcomes in Korean patients with small cell lung cancer. Lung Cancer, 88(3), 325-331. https://doi.org/10.1016/j.lungcan.2015.03.002
Park, Ji Soo ; Lee, Jae Seok ; Kim, Eun Young ; Jung, Ji Ye ; Kim, Se Kyu ; Chang, Joon ; Kim, Dae Joon ; Lee, Chang Young ; Jung, Inkyung ; Kim, Joo Hang ; Kim, Hye Ryun ; Moon, Yong Wha ; Kim, Hyo Song ; Cho, Byoung Chul ; Shim, Hyo Sup. / The frequency and impact of FGFR1 amplification on clinical outcomes in Korean patients with small cell lung cancer. In: Lung Cancer. 2015 ; Vol. 88, No. 3. pp. 325-331.
@article{535bf76d17664937bd249b4f7b55b3a8,
title = "The frequency and impact of FGFR1 amplification on clinical outcomes in Korean patients with small cell lung cancer",
abstract = "Objectives: Fibroblast growth factor receptor 1 (FGFR1) plays a critical role in many human cancers. We tried to identify the frequency of FGFR1 amplifications among Korean patients with small cell lung cancer (SCLC). Additionally, we examined the clinical significance of FGFR1 amplifications for overall survival (OS) and progression-free survival (PFS) among SCLC patients who received standard chemotherapies. Materials and methods: Tumor tissues from 158 Korean patients diagnosed with SCLC from September 2009 to February 2013 were collected and analyzed using an FGFR1 FISH assay with a probe that hybridized to chromosome region 8p12-8p11.23 (Abbott Molecular, Abbott Park, IL). Results and conclusion: FGFR1 amplification was detected in three patients (1.9{\%}) harboring extensive disease (ED). A multivariate analysis showed that among the patients with ED, FGFR1 amplification was associated with shorter disease-free survival to first-line chemotherapy with etoposide plus cisplatin or carboplatin (hazard ratio [HR] = 7.1; 95{\%} confidence interval [CI] = 2.0-25.4; P = 0.003). The median overall survival time of the patients with ED was 8.2 and 10.2 months among patients with and without FGFR1 amplification, respectively (P = 0.37). Although FGFR1 amplification is rare in SCLC compared to non-small cell lung cancer or other malignancies with squamous histology, it is associated with poor survival following standard chemotherapy in SCLC. Further studies in large cohorts of patients with SCLC are needed to verify these results. Our results imply that FGFR1 may be a potential therapeutic target in SCLC and it could be confirmed in a clinical trial.",
author = "Park, {Ji Soo} and Lee, {Jae Seok} and Kim, {Eun Young} and Jung, {Ji Ye} and Kim, {Se Kyu} and Joon Chang and Kim, {Dae Joon} and Lee, {Chang Young} and Inkyung Jung and Kim, {Joo Hang} and Kim, {Hye Ryun} and Moon, {Yong Wha} and Kim, {Hyo Song} and Cho, {Byoung Chul} and Shim, {Hyo Sup}",
year = "2015",
month = "6",
day = "1",
doi = "10.1016/j.lungcan.2015.03.002",
language = "English",
volume = "88",
pages = "325--331",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

Park, JS, Lee, JS, Kim, EY, Jung, JY, Kim, SK, Chang, J, Kim, DJ, Lee, CY, Jung, I, Kim, JH, Kim, HR, Moon, YW, Kim, HS, Cho, BC & Shim, HS 2015, 'The frequency and impact of FGFR1 amplification on clinical outcomes in Korean patients with small cell lung cancer', Lung Cancer, vol. 88, no. 3, pp. 325-331. https://doi.org/10.1016/j.lungcan.2015.03.002

The frequency and impact of FGFR1 amplification on clinical outcomes in Korean patients with small cell lung cancer. / Park, Ji Soo; Lee, Jae Seok; Kim, Eun Young; Jung, Ji Ye; Kim, Se Kyu; Chang, Joon; Kim, Dae Joon; Lee, Chang Young; Jung, Inkyung; Kim, Joo Hang; Kim, Hye Ryun; Moon, Yong Wha; Kim, Hyo Song; Cho, Byoung Chul; Shim, Hyo Sup.

In: Lung Cancer, Vol. 88, No. 3, 01.06.2015, p. 325-331.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The frequency and impact of FGFR1 amplification on clinical outcomes in Korean patients with small cell lung cancer

AU - Park, Ji Soo

AU - Lee, Jae Seok

AU - Kim, Eun Young

AU - Jung, Ji Ye

AU - Kim, Se Kyu

AU - Chang, Joon

AU - Kim, Dae Joon

AU - Lee, Chang Young

AU - Jung, Inkyung

AU - Kim, Joo Hang

AU - Kim, Hye Ryun

AU - Moon, Yong Wha

AU - Kim, Hyo Song

AU - Cho, Byoung Chul

AU - Shim, Hyo Sup

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Objectives: Fibroblast growth factor receptor 1 (FGFR1) plays a critical role in many human cancers. We tried to identify the frequency of FGFR1 amplifications among Korean patients with small cell lung cancer (SCLC). Additionally, we examined the clinical significance of FGFR1 amplifications for overall survival (OS) and progression-free survival (PFS) among SCLC patients who received standard chemotherapies. Materials and methods: Tumor tissues from 158 Korean patients diagnosed with SCLC from September 2009 to February 2013 were collected and analyzed using an FGFR1 FISH assay with a probe that hybridized to chromosome region 8p12-8p11.23 (Abbott Molecular, Abbott Park, IL). Results and conclusion: FGFR1 amplification was detected in three patients (1.9%) harboring extensive disease (ED). A multivariate analysis showed that among the patients with ED, FGFR1 amplification was associated with shorter disease-free survival to first-line chemotherapy with etoposide plus cisplatin or carboplatin (hazard ratio [HR] = 7.1; 95% confidence interval [CI] = 2.0-25.4; P = 0.003). The median overall survival time of the patients with ED was 8.2 and 10.2 months among patients with and without FGFR1 amplification, respectively (P = 0.37). Although FGFR1 amplification is rare in SCLC compared to non-small cell lung cancer or other malignancies with squamous histology, it is associated with poor survival following standard chemotherapy in SCLC. Further studies in large cohorts of patients with SCLC are needed to verify these results. Our results imply that FGFR1 may be a potential therapeutic target in SCLC and it could be confirmed in a clinical trial.

AB - Objectives: Fibroblast growth factor receptor 1 (FGFR1) plays a critical role in many human cancers. We tried to identify the frequency of FGFR1 amplifications among Korean patients with small cell lung cancer (SCLC). Additionally, we examined the clinical significance of FGFR1 amplifications for overall survival (OS) and progression-free survival (PFS) among SCLC patients who received standard chemotherapies. Materials and methods: Tumor tissues from 158 Korean patients diagnosed with SCLC from September 2009 to February 2013 were collected and analyzed using an FGFR1 FISH assay with a probe that hybridized to chromosome region 8p12-8p11.23 (Abbott Molecular, Abbott Park, IL). Results and conclusion: FGFR1 amplification was detected in three patients (1.9%) harboring extensive disease (ED). A multivariate analysis showed that among the patients with ED, FGFR1 amplification was associated with shorter disease-free survival to first-line chemotherapy with etoposide plus cisplatin or carboplatin (hazard ratio [HR] = 7.1; 95% confidence interval [CI] = 2.0-25.4; P = 0.003). The median overall survival time of the patients with ED was 8.2 and 10.2 months among patients with and without FGFR1 amplification, respectively (P = 0.37). Although FGFR1 amplification is rare in SCLC compared to non-small cell lung cancer or other malignancies with squamous histology, it is associated with poor survival following standard chemotherapy in SCLC. Further studies in large cohorts of patients with SCLC are needed to verify these results. Our results imply that FGFR1 may be a potential therapeutic target in SCLC and it could be confirmed in a clinical trial.

UR - http://www.scopus.com/inward/record.url?scp=84929520145&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929520145&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2015.03.002

DO - 10.1016/j.lungcan.2015.03.002

M3 - Article

C2 - 25819384

AN - SCOPUS:84929520145

VL - 88

SP - 325

EP - 331

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 3

ER -